04:28 PM EST, 11/26/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) reported a fiscal Q4 loss late Tuesday of $5.00 per diluted share, widening from a loss of $1.92 a year earlier.
Analysts polled by FactSet, on average, expected a $0.97 loss.
Revenue for the quarter ended Sept. 30 was $3.6 million, compared with $240.8 million a year earlier.
Analysts expected $55.1 million.